U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C8H8F3N3O4S2
Molecular Weight 331.2945
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of HYDROFLUMETHIAZIDE

SMILES

c1c(c(cc2c1NCNS2(=O)=O)S(=O)(=O)N)C(F)(F)F

InChI

InChIKey=DMDGGSIALPNSEE-UHFFFAOYSA-N
InChI=1S/C8H8F3N3O4S2/c9-8(10,11)4-1-5-7(2-6(4)19(12,15)16)20(17,18)14-3-13-5/h1-2,13-14H,3H2,(H2,12,15,16)

HIDE SMILES / InChI

Description
Curator's Comment:: Description was created based on several sources, including https://www.drugs.com/pro/saluron.html

Hydroflumethiazide is a thiazide diuretic that inhibits water reabsorption in the nephron by inhibiting the sodium-chloride symporter (SLC12A3) in the distal convoluted tubule, which is responsible for 5% of total sodium reabsorption. Normally, the sodium-chloride symporter transports sodium and chloride from the lumen into the epithelial cell lining the distal convoluted tubule. The energy for this is provided by a sodium gradient established by sodium-potassium ATPases on the basolateral membrane. Once sodium has entered the cell, it is transported out into the basolateral interstitium via the sodium-potassium ATPase, causing an increase in the osmolarity of the interstitium, thereby establishing an osmotic gradient for water reabsorption. By blocking the sodium-chloride symporter, Hydroflumethiazide effectively reduces the osmotic gradient and water reabsorption throughout the nephron. Hydroflumethiazide is used as adjunctive therapy in edema associated with congestive heart failure, hepatic cirrhosis, and corticosteroid and estrogen therapy. Also used in the management of hypertension either as the sole therapeutic agent or to enhance the effect of other antihypertensive drugs in the more severe forms of hypertension.

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
SALURON

Approved Use

Saluron® is indicated as adjunctive therapy in edema associated with congestive heart failure, hepatic cirrhosis and corticosteroid and estrogen therapy. Saluron® has also been found useful in edema due to various forms of renal dysfunction, such as nephrotic syndrome, acute glomerulonephritis, and chronic renal failure. Saluron® is indicated in the management of hypertension, either as the sole therapeutic agent or to enhance the effectiveness of other antihypertensive drugs in the more severe forms of hypertension.

Launch Date

-3.29788785E11
Primary
SALURON

Approved Use

Saluron® is indicated as adjunctive therapy in edema associated with congestive heart failure, hepatic cirrhosis and corticosteroid and estrogen therapy. Saluron® has also been found useful in edema due to various forms of renal dysfunction, such as nephrotic syndrome, acute glomerulonephritis, and chronic renal failure. Saluron® is indicated in the management of hypertension, either as the sole therapeutic agent or to enhance the effectiveness of other antihypertensive drugs in the more severe forms of hypertension.

Launch Date

-3.29788785E11
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
0.389 μg/mL
100 mg single, oral
dose: 100 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
HYDROFLUMETHIAZIDE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
1.717 μg × h/mL
100 mg single, oral
dose: 100 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
HYDROFLUMETHIAZIDE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
13.12 μM × h
25 mg single, oral
dose: 25 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
HYDROFLUMETHIAZIDE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: MALE
food status: FASTED
9.83 μM × h
25 mg single, oral
dose: 25 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
HYDROFLUMETHIAZIDE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
2 h
100 mg single, oral
dose: 100 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
HYDROFLUMETHIAZIDE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
9.6 h
25 mg single, oral
dose: 25 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
HYDROFLUMETHIAZIDE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: MALE
food status: FASTED
16.6 h
25 mg single, oral
dose: 25 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
HYDROFLUMETHIAZIDE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
Doses

Doses

DosePopulationAdverse events​
0.8 g single, oral
Highest studied dose
Dose: 0.8 g
Route: oral
Route: single
Dose: 0.8 g
Sources: Page: p.56
unhealthy, 32 - 80
n = 16
Health Status: unhealthy
Condition: Edema
Age Group: 32 - 80
Sex: M+F
Population Size: 16
Sources: Page: p.56
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG

OverviewOther

Other InhibitorOther SubstrateOther Inducer

Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
yes
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
yes
PubMed

PubMed

TitleDatePubMed
Gas-phase behaviour of negative ions produced from thiazidic diuretics under electrospray conditions.
2002 Sep
Tumor estrogen content and clinico-morphological and endocrine features of endometrial cancer.
2003 Apr
High-speed gas chromatography in doping control: fast-GC and fast-GC/MS determination of beta-adrenoceptor ligands and diuretics.
2006 Dec
Fast gas chromatographic/mass spectrometric determination of diuretics and masking agents in human urine: Development and validation of a productive screening protocol for antidoping analysis.
2006 Dec 1
Chloro-thia-zide-pyridine (1/3).
2008 May 17
Interfacing on-line solid phase extraction with monolithic column multisyringe chromatography and chemiluminescence detection: An effective tool for fast, sensitive and selective determination of thiazide diuretics.
2010 Jan 15
Patents

Sample Use Guides

In Vivo Use Guide
In the treatment of edema, the usual initial dose is 50 to 200 mg daily, in 1 or 2 divided doses, reduced to a dose of 25 to 50 mg on alternate days or intermittently. In the treatment of hypertension, the usual dose is 25 to 50 mg daily in 1 or 2 divided doses, either alone, or in conjunction with other antihypertensive agents. A suggested initial dose for children is 1 mg per kg of body weight daily, reduced for maintenance.
Route of Administration: Oral
In Vitro Use Guide
Hydroflumethiazide at concentrations ranging from 1 to 50 ug/mL stimulated the normal secretion of glucagon, insulin, and somatostatin in a dose-dependent manner in isolated perfused pancreas of normal and alloxan diabetic dogs.
Name Type Language
HYDROFLUMETHIAZIDE
HSDB   INN   JAN   MART.   MI   ORANGE BOOK   USP   USP-RS   VANDF   WHO-DD  
INN  
Official Name English
HYDROFLUMETHIAZIDE [VANDF]
Common Name English
3,4-DIHYDRO-6-(TRIFLUOROMETHYL)-2H-1,2,4-BENZOTHIADIAZINE-7-SULFONAMIDE 1,1-DIOXIDE
Systematic Name English
HYDROFLUMETHIAZIDE [JAN]
Common Name English
HYDROFLUMETHIAZIDE [INN]
Common Name English
HYDROFLUMETHIAZIDE [MI]
Common Name English
HYDROFLUMETHIAZIDE [HSDB]
Common Name English
SALURON
Brand Name English
HYDROFLUMETHIAZIDE [USP]
Common Name English
DIUCARDIN
Brand Name English
NSC-44627
Code English
HYDROFLUMETHIAZIDE [ORANGE BOOK]
Common Name English
HYDROFLUMETHIAZIDE [USP-RS]
Common Name English
2H-1,2,4-BENZOTHIADIAZINE-7-SULFONAMIDE, 3,4-DIHYDRO-6-(TRIFLUOROMETHYL)-, 1,1-DIOXIDE
Systematic Name English
HYDROFLUMETHIAZIDE COMPONENT OF SALUTENSIN
Common Name English
HYDROFLUMETHIAZIDE [MART.]
Common Name English
SALUTENSIN COMPONENT HYDROFLUMETHIAZIDE
Common Name English
HYDROFLUMETHIAZIDE [WHO-DD]
Common Name English
Classification Tree Code System Code
LIVERTOX 486
Created by admin on Sat Jun 26 14:10:44 UTC 2021 , Edited by admin on Sat Jun 26 14:10:44 UTC 2021
WHO-ATC C03AH02
Created by admin on Sat Jun 26 14:10:44 UTC 2021 , Edited by admin on Sat Jun 26 14:10:44 UTC 2021
WHO-VATC QC03AH02
Created by admin on Sat Jun 26 14:10:44 UTC 2021 , Edited by admin on Sat Jun 26 14:10:44 UTC 2021
NDF-RT N0000166469
Created by admin on Sat Jun 26 14:10:44 UTC 2021 , Edited by admin on Sat Jun 26 14:10:44 UTC 2021
NDF-RT N0000166469
Created by admin on Sat Jun 26 14:10:44 UTC 2021 , Edited by admin on Sat Jun 26 14:10:44 UTC 2021
WHO-ATC C03AB02
Created by admin on Sat Jun 26 14:10:44 UTC 2021 , Edited by admin on Sat Jun 26 14:10:44 UTC 2021
NCI_THESAURUS C49185
Created by admin on Sat Jun 26 14:10:44 UTC 2021 , Edited by admin on Sat Jun 26 14:10:44 UTC 2021
NDF-RT N0000175419
Created by admin on Sat Jun 26 14:10:44 UTC 2021 , Edited by admin on Sat Jun 26 14:10:44 UTC 2021
NDF-RT N0000175359
Created by admin on Sat Jun 26 14:10:44 UTC 2021 , Edited by admin on Sat Jun 26 14:10:44 UTC 2021
WHO-VATC QC03AB02
Created by admin on Sat Jun 26 14:10:44 UTC 2021 , Edited by admin on Sat Jun 26 14:10:44 UTC 2021
WHO-ATC C03AA02
Created by admin on Sat Jun 26 14:10:44 UTC 2021 , Edited by admin on Sat Jun 26 14:10:44 UTC 2021
WHO-VATC QC03AA02
Created by admin on Sat Jun 26 14:10:44 UTC 2021 , Edited by admin on Sat Jun 26 14:10:44 UTC 2021
Code System Code Type Description
DRUG CENTRAL
1392
Created by admin on Sat Jun 26 14:10:44 UTC 2021 , Edited by admin on Sat Jun 26 14:10:44 UTC 2021
PRIMARY
NCI_THESAURUS
C47557
Created by admin on Sat Jun 26 14:10:44 UTC 2021 , Edited by admin on Sat Jun 26 14:10:44 UTC 2021
PRIMARY
WIKIPEDIA
HYDROFLUMETHIAZIDE
Created by admin on Sat Jun 26 14:10:44 UTC 2021 , Edited by admin on Sat Jun 26 14:10:44 UTC 2021
PRIMARY
CAS
135-09-1
Created by admin on Sat Jun 26 14:10:44 UTC 2021 , Edited by admin on Sat Jun 26 14:10:44 UTC 2021
PRIMARY
MESH
D006857
Created by admin on Sat Jun 26 14:10:44 UTC 2021 , Edited by admin on Sat Jun 26 14:10:44 UTC 2021
PRIMARY
ChEMBL
CHEMBL1763
Created by admin on Sat Jun 26 14:10:44 UTC 2021 , Edited by admin on Sat Jun 26 14:10:44 UTC 2021
PRIMARY
PUBCHEM
3647
Created by admin on Sat Jun 26 14:10:44 UTC 2021 , Edited by admin on Sat Jun 26 14:10:44 UTC 2021
PRIMARY
HSDB
3340
Created by admin on Sat Jun 26 14:10:44 UTC 2021 , Edited by admin on Sat Jun 26 14:10:44 UTC 2021
PRIMARY
EPA CompTox
135-09-1
Created by admin on Sat Jun 26 14:10:44 UTC 2021 , Edited by admin on Sat Jun 26 14:10:44 UTC 2021
PRIMARY
ECHA (EC/EINECS)
205-173-8
Created by admin on Sat Jun 26 14:10:44 UTC 2021 , Edited by admin on Sat Jun 26 14:10:44 UTC 2021
PRIMARY
EVMPD
SUB08067MIG
Created by admin on Sat Jun 26 14:10:44 UTC 2021 , Edited by admin on Sat Jun 26 14:10:44 UTC 2021
PRIMARY
INN
895
Created by admin on Sat Jun 26 14:10:44 UTC 2021 , Edited by admin on Sat Jun 26 14:10:44 UTC 2021
PRIMARY
USP_CATALOG
1322007
Created by admin on Sat Jun 26 14:10:44 UTC 2021 , Edited by admin on Sat Jun 26 14:10:44 UTC 2021
PRIMARY USP-RS
MERCK INDEX
M6096
Created by admin on Sat Jun 26 14:10:44 UTC 2021 , Edited by admin on Sat Jun 26 14:10:44 UTC 2021
PRIMARY Merck Index
IUPHAR
7197
Created by admin on Sat Jun 26 14:10:44 UTC 2021 , Edited by admin on Sat Jun 26 14:10:44 UTC 2021
PRIMARY
RXCUI
5495
Created by admin on Sat Jun 26 14:10:44 UTC 2021 , Edited by admin on Sat Jun 26 14:10:44 UTC 2021
PRIMARY RxNorm
FDA UNII
501CFL162R
Created by admin on Sat Jun 26 14:10:44 UTC 2021 , Edited by admin on Sat Jun 26 14:10:44 UTC 2021
PRIMARY
DRUG BANK
DB00774
Created by admin on Sat Jun 26 14:10:44 UTC 2021 , Edited by admin on Sat Jun 26 14:10:44 UTC 2021
PRIMARY
LACTMED
Hydroflumethiazide
Created by admin on Sat Jun 26 14:10:44 UTC 2021 , Edited by admin on Sat Jun 26 14:10:44 UTC 2021
PRIMARY